FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2750537112> ?p ?o ?g. }

• W2750537112 endingPage "2162" @default.
• W2750537112 startingPage "2150" @default.
• W2750537112 abstract "Asian patients with type 2 diabetes (T2D) are younger, leaner, and more likely to develop renal dysfunction than White populations. In this multiethnic analysis of data from phase 3 trials, we investigated the efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in Asians stratified by these subphenotypes. Data from randomized, double-blind, placebo-controlled trials evaluating linagliptin (as monotherapy, add-on therapy to metformin ± sulfonylurea, combined with pioglitazone or added to insulin) were pooled with efficacy data from 11 randomized trials of at least 24 weeks and safety data from 15 trials of various durations. In the efficacy set, 1404 Asian patients received linagliptin [mean (standard deviation) age 54.5 (10.1) years; body mass index (BMI) 26.0 (3.9) kg/m2] and 661 received placebo [age 55.0 (9.7) years; BMI 26.1 (3.9) kg/m2] with the same glycated hemoglobin (HbA1c): 8.2 (0.9)% in both groups. At 24 weeks, the placebo-corrected adjusted mean ± standard error change from baseline in HbA1c with linagliptin was −0.73 ± 0.04% (95% confidence interval −0.81, −0.65; P < 0.0001). Reductions in HbA1c were similar upon stratification by age [<65 years, −0.71 ± 0.05% (−0.80, −0.62; P < 0.0001); ≥65 years, −0.81 ± 0.10% (−1.01, −0.60; P < 0.0001)], BMI (<25 kg/m2, −0.82 ± 0.06% [−0.94, −0.70; P < 0.0001]; ≥25 kg/m2, −0.65 ± 0.06% [−0.76, −0.54; P < 0.0001]) and estimated glomerular filtration rate [<90 mL/min/1.73 m2, −0.71 ± 0.06% (−0.82, −0.60; P < 0.0001); ≥90 mL/min/1.73 m2, −0.75 ± 0.06% (−0.87, −0.64; P < 0.0001)]. In the safety set (linagliptin, n = 1842; placebo, n = 839), 52.2% and 54.6% of patients, respectively, experienced adverse events. The rates of drug-related adverse events were 10.9% in the linagliptin group and 10.4% in the placebo group. The respective rates of hypoglycemia were 8.3% and 9.5%, mainly among patients treated with sulfonylurea or insulin. Severe hypoglycemia was rare (<1.0% in either group). Linagliptin effectively reduced hyperglycemia in Asian patients with uncontrolled T2D, irrespective of age, BMI, renal function, or ethnic subgroups, and was well tolerated. Boehringer Ingelheim, Eli Lilly and Company, and the Diabetes Alliance." @default.
• W2750537112 created "2017-08-31" @default.
• W2750537112 creator A5019886336 @default.
• W2750537112 creator A5025609173 @default.
• W2750537112 creator A5061331585 @default.
• W2750537112 creator A5069611208 @default.
• W2750537112 creator A5091832416 @default.
• W2750537112 date "2017-08-17" @default.
• W2750537112 modified "2023-10-18" @default.
• W2750537112 title "Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials" @default.
• W2750537112 cites W1490158739 @default.
• W2750537112 cites W1513833217 @default.
• W2750537112 cites W1738952274 @default.
• W2750537112 cites W1771498646 @default.
• W2750537112 cites W1900988681 @default.
• W2750537112 cites W1911149840 @default.
• W2750537112 cites W1969276623 @default.
• W2750537112 cites W1972215659 @default.
• W2750537112 cites W1981024765 @default.
• W2750537112 cites W1992562407 @default.
• W2750537112 cites W1994433330 @default.
• W2750537112 cites W1998401806 @default.
• W2750537112 cites W2002080901 @default.
• W2750537112 cites W2005041748 @default.
• W2750537112 cites W2046505026 @default.
• W2750537112 cites W2047150424 @default.
• W2750537112 cites W2056526409 @default.
• W2750537112 cites W2060473900 @default.
• W2750537112 cites W2067663978 @default.
• W2750537112 cites W2073068020 @default.
• W2750537112 cites W2074142099 @default.
• W2750537112 cites W2081936370 @default.
• W2750537112 cites W2090078712 @default.
• W2750537112 cites W2098292453 @default.
• W2750537112 cites W2100987099 @default.
• W2750537112 cites W2109688740 @default.
• W2750537112 cites W2109911153 @default.
• W2750537112 cites W2127825630 @default.
• W2750537112 cites W2128648250 @default.
• W2750537112 cites W2130944773 @default.
• W2750537112 cites W2139923324 @default.
• W2750537112 cites W2140480989 @default.
• W2750537112 cites W2144193100 @default.
• W2750537112 cites W2146898936 @default.
• W2750537112 cites W2147698512 @default.
• W2750537112 cites W2149894478 @default.
• W2750537112 cites W2149967041 @default.
• W2750537112 cites W2159205789 @default.
• W2750537112 cites W2159430955 @default.
• W2750537112 cites W2171289017 @default.
• W2750537112 cites W2176616614 @default.
• W2750537112 cites W2190797165 @default.
• W2750537112 cites W2236050786 @default.
• W2750537112 cites W2463450500 @default.
• W2750537112 cites W2510002117 @default.
• W2750537112 cites W2555324093 @default.
• W2750537112 cites W993165172 @default.
• W2750537112 doi "https://doi.org/10.1007/s12325-017-0595-7" @default.
• W2750537112 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5599450" @default.
• W2750537112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28819835" @default.
• W2750537112 hasPublicationYear "2017" @default.
• W2750537112 type Work @default.
• W2750537112 sameAs 2750537112 @default.
• W2750537112 citedByCount "10" @default.
• W2750537112 countsByYear W27505371122019 @default.
• W2750537112 countsByYear W27505371122020 @default.
• W2750537112 countsByYear W27505371122021 @default.
• W2750537112 countsByYear W27505371122022 @default.
• W2750537112 crossrefType "journal-article" @default.
• W2750537112 hasAuthorship W2750537112A5019886336 @default.
• W2750537112 hasAuthorship W2750537112A5025609173 @default.
• W2750537112 hasAuthorship W2750537112A5061331585 @default.
• W2750537112 hasAuthorship W2750537112A5069611208 @default.
• W2750537112 hasAuthorship W2750537112A5091832416 @default.
• W2750537112 hasBestOaLocation W27505371121 @default.
• W2750537112 hasConcept C126322002 @default.
• W2750537112 hasConcept C134018914 @default.
• W2750537112 hasConcept C142724271 @default.
• W2750537112 hasConcept C159641895 @default.
• W2750537112 hasConcept C168563851 @default.
• W2750537112 hasConcept C204787440 @default.
• W2750537112 hasConcept C27081682 @default.
• W2750537112 hasConcept C2777180221 @default.
• W2750537112 hasConcept C2777538456 @default.
• W2750537112 hasConcept C2778384471 @default.
• W2750537112 hasConcept C2779306644 @default.
• W2750537112 hasConcept C2780031085 @default.
• W2750537112 hasConcept C2780221984 @default.
• W2750537112 hasConcept C2780323712 @default.
• W2750537112 hasConcept C44249647 @default.
• W2750537112 hasConcept C555293320 @default.
• W2750537112 hasConcept C71924100 @default.
• W2750537112 hasConcept C90924648 @default.
• W2750537112 hasConceptScore W2750537112C126322002 @default.
• W2750537112 hasConceptScore W2750537112C134018914 @default.
• W2750537112 hasConceptScore W2750537112C142724271 @default.
• W2750537112 hasConceptScore W2750537112C159641895 @default.
• W2750537112 hasConceptScore W2750537112C168563851 @default.

• next